Today: 17 May 2026
Visa stock set for Monday as Mexico blocks Prosa deal after the bell
22 February 2026
2 mins read

Visa stock set for Monday as Mexico blocks Prosa deal after the bell

New York, Feb 22, 2026, 13:26 EST — The session ended with the market closed.

  • Visa’s bid to buy a 51% stake in Mexican payments processor Prosa has been nixed by Mexico’s antitrust authority.
  • Visa finished Friday’s session up 0.63%. The regulator’s decision landed after the bell.
  • Traders this week are zeroing in on Visa’s moves in Mexico, plus scanning the broader market for fresh reads on tariffs and inflation.

Mexico’s National Antitrust Commission has blocked Visa’s planned move to acquire 51% of payment processor Prosa, handing down the decision late Friday. The regulator cited potential risks to the financial system, saying the tie-up between the global card network and a big domestic processor—owner of the Carnet card brand—would hurt competition. The ruling could sway the stock when U.S. markets open Monday.

This decision drops on a weekend, which means markets get no time to stagger their reaction—everything hits at Monday’s open. The regulator’s tone is hard to miss. Not only did it claim the deal wipes out a direct competitor, but it flagged Visa’s potential grab of rivals’ transaction data—a level of scrutiny regulators often save for headline cases.

Visa finished Friday at $320.95, gaining 0.63%, after moving in a $317.82 to $322.35 range. News of the Mexico decision emerged after the bell, teeing up potential gap risk for the upcoming session rather than the one just wrapped.

Visa didn’t hold back, labeling the move a blow to both competition and modernization. The company, in a statement, said it’s “disappointed” by the ruling and “carefully reviewing” its next steps, adding that it “will evaluate all available options.” Visa Corporate

Visa barely budged in quiet after-hours action, ticking up just 0.02% to $321.00. These sessions often see light volume and choppy price moves on even minor news.

Traders pushed into riskier assets as the weekend approached. U.S. stocks closed out Friday in positive territory, reacting to the Supreme Court’s decision to overturn President Donald Trump’s global tariffs. Investors also digested Trump’s subsequent move—a short-term 10% tariff—which seemed to provide some relief. “Today is a removal of some uncertainty, and we’re on to the next phase,” said Mike Dickson, Horizon Investments’ head of research and quantitative strategies. Reuters

Macro drivers didn’t quite line up. U.S. economic growth lost momentum in the fourth quarter, Friday’s data showed, while December’s Personal Consumption Expenditures (PCE) price index—the Fed’s preferred inflation metric—picked up speed, complicating the outlook for rate cuts. “Striking down of these tariffs will benefit corporate bottom lines, corporate earnings,” said Tim Ghriskey, senior portfolio strategist at Ingalls & Snyder. Still, he cautioned, policy shifts could rattle markets. Reuters

Payments stocks tracked broader moves Friday, with Mastercard picking up 1.18% to close at $526.41. The gain put it ahead of Visa for the session as traders favored large-cap financial and payments shares.

The setback in Mexico is the kind of regulatory overhang that tends to linger. Should Visa fail to resurrect the Prosa transaction—or if delays mount—it risks complicating ambitions to expand its local processing footprint. That could also draw sharper scrutiny from investors, who may start eyeing other regions where regulators could resist.

Looking ahead, traders are set to scrutinize any updates on Visa’s plans in Mexico, following the company’s announcement that it’s weighing its options. Alongside that, markets are on alert for potential tariff developments and a packed earnings slate, with Nvidia slated to report results this Wednesday, Feb. 25.

Stock Market Today

  • XRP Price Declines Amid Bearish Pressure Near $1.50 Resistance
    May 17, 2026, 5:46 AM EDT. Ripple's XRP is sliding, currently testing support at $1.43. The cryptocurrency faces significant selling pressure near $1.50, which has restricted gains since Monday. This resistance zone is acting as a ceiling, triggering bearish movements and weighing on XRP's short-term outlook.

Latest articles

E-Power Stock Drops Again: Why EPOW’s 66-Cent Close Sets Up a Tense Week

E-Power Stock Drops Again: Why EPOW’s 66-Cent Close Sets Up a Tense Week

17 May 2026
E-Power Inc. shares closed at $0.66 Friday, down 7.04%, after its annual report showed a 28.59% drop in net revenue to $46.4 million and a widened net loss of $26.66 million, citing “substantial doubt” about its ability to continue as a going concern. The Nasdaq Composite also fell 1.54% Friday, ending a six-week rally. E-Power announced new patents and a $252 million microgrid project earlier in the week.
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 17.05.2026

17 May 2026
LIVEMarkets rolling coverageStarted: May 17, 2026, 4:00 AM EDTUpdated: May 17, 2026, 5:54 AM EDT XRP Price Declines Amid Bearish Pressure Near $1.50 Resistance May 17, 2026, 5:46 AM EDT. Ripple’s XRP is sliding, currently testing support at $1.43. The cryptocurrency faces significant selling pressure near $1.50, which has restricted gains since Monday. This resistance zone is acting as a ceiling, triggering bearish movements and weighing on XRP’s short-term outlook. Why is XRP falling? INFRONEER Holdings' New Stock Grant Trust and Governance Shift Impact Investment Outlook May 17, 2026, 5:45 AM EDT. INFRONEER Holdings Inc. (TSE:5076) reported fiscal 2026 results
Joby Aviation Slides Monday With Air-Taxi in Focus

Joby Aviation Slides Monday With Air-Taxi in Focus

17 May 2026
Joby Aviation shares closed Friday at $10.36, down 2.6% for the day and 4.7% for the week. CEO JoeBen Bevirt-linked trusts sold over 421,000 shares under a preset 10b5-1 plan, filings showed. The stock traded between $10.04 and $10.58 during a volatile week. Broader markets and eVTOL sector peers also declined.
ImmunityBio’s BCG Agreement Puts Monday’s Trading in Focus

ImmunityBio’s BCG Agreement Puts Monday’s Trading in Focus

17 May 2026
ImmunityBio closed at $7.97 Friday, down 2.2% after announcing exclusive U.S. rights to Japan BCG Laboratory’s Tokyo-172 strain for bladder cancer therapy. The Tokyo strain remains investigational in the U.S. and is not FDA-approved. Nasdaq was closed for the weekend; the next trading session is Monday. ImmunityBio’s Q1 product revenue rose to $44.2 million with $380.9 million in cash and securities.
Salesforce stock (CRM) steadies, but Wall Street trims targets again ahead of Feb. 25 results
Previous Story

Salesforce stock (CRM) steadies, but Wall Street trims targets again ahead of Feb. 25 results

Plug Power stock dips before the bell as tariff jitters and dilution fears linger
Next Story

Plug Power stock dips before the bell as tariff jitters and dilution fears linger

Go toTop